Hospital admissions · patients with chronic obstructive pulmonary disease
It is very uncertain whether once‐daily ICS/LABA combined inhalers changes hospital admissions (all‐cause) compared with once‐daily LAMA (very low certainty).
1 finding from 1 review
Exacerbations leading to intubation · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Physical activity measure (e.g. 6MWT) · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Change from baseline in mean asthma symptom score Greater the reduction, better the outcome Duration of trials: 12 to 13 weeks · adults and adolescents with persistent asthma
1 finding from 1 review
Intervention not reported
Overall adverse effects Duration of trials: 8 to 16 weeks · adults and adolescents with persistent asthma
The intervention showed no clear difference in overall adverse effects Duration of trials: 8 to 16 weeks (low certainty).
1 finding from 1 review
Intervention not reported
Death Duration of trials: 12 to 13 weeks · adults and adolescents with persistent asthma
1 finding from 1 review
Intervention not reported
% change from baseline ICS dose Duration of trials: 12 to 24 weeks More reduction is better · adults and adolescents with persistent asthma
1 finding from 1 review
Intervention not reported
Change from baseline in morning PEFR (L/min) Duration of trials: 12 to 24 weeks · adults and adolescents with persistent asthma
1 finding from 1 review
Intervention not reported
Overall adverse effects Duration of trials: 8 to 24 weeks · adults and adolescents with persistent asthma
The intervention showed no clear difference in overall adverse effects Duration of trials: 8 to 24 weeks (moderate certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events Duration of trials: 12 to 20 weeks · adults and adolescents with persistent asthma
The intervention probably leads to higher serious adverse events Duration of trials: 12 to 20 weeks (moderate certainty).
1 finding from 1 review
Intervention not reported
Death Duration of trials: 8 to 24 weeks · adults and adolescents with persistent asthma
The intervention showed no clear difference in death Duration of trials: 8 to 24 weeks (low certainty).
1 finding from 1 review
Intervention not reported
Change from baseline in morning PEFR (L/min) Duration of trials: 6 to 16 weeks · adults and adolescents with persistent asthma
1 finding from 1 review
Intervention not reported
Change from baseline FEV1 (L) Duration of trials: 6 to 16 weeks · adults and adolescents with persistent asthma
1 finding from 1 review
Intervention not reported
Change from baseline in mean asthma symptom score (daytime) Greater the reduction, better the outcome Duration of trials: 6 to 16 weeks · adults and adolescents with persistent asthma
1 finding from 1 review
Intervention not reported
Overall adverse effects Duration of trials: 6 to 16 weeks · adults and adolescents with persistent asthma
The intervention showed no clear difference in overall adverse effects Duration of trials: 6 to 16 weeks (moderate certainty).
1 finding from 1 review
Intervention not reported
Death Duration of trials: 6 to 16 weeks · adults and adolescents with persistent asthma
The intervention showed no clear difference in death Duration of trials: 6 to 16 weeks (low certainty).
1 finding from 1 review
Intervention not reported
Change from baseline in morning PEFR (L/min) Duration of trials: 8 to 13 weeks · adults and adolescents with persistent asthma
1 finding from 1 review
Intervention not reported
Change from baseline FEV1 (L) Duration of trials: 8 to 13 weeks · adults and adolescents with persistent asthma
1 finding from 1 review
Rate of exacerbations requiring systemic corticosteroids · adults with asthma
It is very uncertain whether ICS dose reduction changes exacerbation requiring OCS compared with no change (very low certainty).
2 findings from 1 review
SAEs · adults with asthma
ICS dose reduction showed no clear difference in all‐cause SAEs compared with no change (low certainty).
2 findings from 1 review